ulrich medical USA Welcomes Alissa Calaway as New Director of U.S. Clinical Affairs

On March 5, 2026, ulrich medical USA confirmed the appointment of Alissa Calaway, RN, MSN, as the Director of U.S. Clinical Affairs. This significant hire is part of a broader strategy to deepen the company's focus on evidence-based innovations in spine surgery. Alongside Calaway’s appointment, ulrich medical USA is launching a comprehensive Clinical Research Program aimed at generating clinical evidence to underscore product safety and performance.

Alissa Calaway brings over 17 years of expertise in clinical operations, specifically in evidence generation strategy and regulatory compliance within the medical device sector. As Director of U.S. Clinical Affairs, she will oversee the execution of the clinical affairs strategy at ulrich medical, which includes a range of investigative studies and clinical research initiatives targeting the spinal implant sector.

Calaway's role is crucial, particularly as clinical research is pivotal in ensuring device safety, verifying performance, and demonstrating tangible patient outcomes. The newly launched Clinical Research Program will emphasize essential endpoints for spine surgeons, such as fusion outcomes, complication rates, and functional recovery metrics.

With this structured approach, ulrich medical USA intends to generate high-quality clinical data that:
1. Enhances patient safety through systematic monitoring of outcomes and adverse events.
2. Supports regulatory submissions and global market access with robust, standards-aligned evidence.
3. Strengthens the confidence of surgeons with peer-reviewed data and insights on real-world performance.
4. Improves product development through informed feedback across the product lifecycle.
5. Differentiates technologies in the highly competitive spine market through clinically substantiated value.

"High-quality clinical evidence is fundamental to responsible innovation in spine surgery," remarked Calaway. "I’m proud to lead initiatives that ensure our technologies are validated through meaningful patient outcomes and that support surgeons in delivering the best possible care."

Under Calaway’s guidance, the Clinical Affairs branch will collaborate closely with various teams, including Research and Development, Regulatory Affairs, Quality, and Commercial sectors, to seamlessly integrate clinical evidence generation from the initial product strategy to post-market evaluations. This cross-functional approach ensures valuable clinical insights influence product development, risk management, labeling, surgeon education, and ongoing performance assessment.

Eric Lucas, PhD, Global Vice President of R&D for Spine at ulrich medical stated, "Expanding our clinical research efforts reflects our commitment to scientific rigor and to building strong partnerships within the spine community. Clinical data allows us to help surgeons while confidently delivering technologies that enhance patient outcomes."

Founded in Plano, Texas, ulrich medical USA is a leading developer of innovative spinal implant systems and surgical instruments designed to improve surgical precision and patient outcomes. Their mission underscores the integration of groundbreaking technology and thorough research, establishing a new standard for the industry. To learn more about their dedication to spine innovations and their complete range of surgical solutions, visit www.ulrichmedicalusa.com.